Epidemiology
Nearly 1 in 500 adults will be diagnosed with CML in their lifetime. CML in children on the other hand is rare with an annual incidence of between one and two cases for every million children under the age of 18 in the United States. Both children and adults can present in one of three phases: (1) nearly 90% present in the chronic phase which is the most common and indolent, (2) accelerated phase is more aggressive and (3) blast phase, upon transformation to an acute leukemia, either ALL or AML. In general, children appear to have higher risk disease with more frequent presentation in accelerated or blast phase compared to adults.
Pathogenesis
CML is an MPN that occurs in HSCs. In children, it always presents with the Philadelphia chromosome t(9;22)(q34;q11), leading to the fusion gene, BCR-ABL1. This encodes for an oncoprotein, leading to a constitutively active tyrosine kinase as a result of oligomerization of the coiled coil region of BCR, and deletion of the inhibitory SH3 domain of ABL. Several downstream pathways are then activated including JAK2, RAS, and STAT1/5. Nearly 90% of patients present in the chronic phase of the disease, but the events leading to the more advanced accelerated phase and blast crisis are incompletely understood. Typically, cytogenetic changes involving the acquisition of additional oncogenes or loss of tumor suppressors is noted. The single most common alteration involves deletion of 17q, where p53 resides, but non-random changes involving chromosomes 7, 8, 9, and 22 are frequent. Patients who transform to acute lymphoblastic leukemia frequently present with loss of CDKN2A/B. In general, it is thought that constitutive activation of BCR/ABL1 leads to an unstable genome within the mutated HSC, which results in the increased likelihood of non-random changes involving genes with critical functions that are more likely to be tolerated due to impaired apoptosis.
Clinical Manifestations
Children with CML frequently present with elevated white blood cell and platelet counts. These can be detected in the asymptomatic patient but more frequently due to fatigue, malaise or weight loss. Patients can also present with concomitant infections due to non functional neutrophils. Enlargement of the spleen is nearly universal at diagnosis and can cause abdominal discomfort. Bleeding due to thrombocytopenia, coagulation defects, or even thrombocytosis with an acquired von Willebrand’s disease can be presenting symptoms.
Laboratory Manifestations
CML patients present with a median elevated white blood count of 250 × 108/l per an international registry study of nearly 200 pediatric patients with a median age of 12 years. Owing to the myeloproliferative nature of the disease, nearly all types of myeloid cells will be visible on a peripheral blood smear, with basophilia and eosinophilia being nearly universal. Blasts are typically < 2%, although it can be higher depending on the phase of presentation. A CBC and FISH, or RT-PCR for BCR/ABL, can be performed although a BM examination that rules out the more common diagnosis of AML is required. Cytogenetic culture is typically sent from the BM. Next-generation sequencing is more commonly sent at diagnosis to determine the presence of tyrosine kinase inhibitor (TKI) resistance mutations although the therapeutic utility of this approach has not been definitively documented.
Therapy
As a poster child for precision medicine, the advent of TKIs demonstrated remarkable efficacy in CML, first in adults and later in children. A paradigm shift occurred in adults, wherein CML became a chronic manageable condition in the setting of TKIs, of which several generations of increasingly potent drugs are now available. In pediatrics, whereas HSCT was indicated for nearly all patients in the pre-TKI era, it is now reserved for patients who present in an accelerated or blast crisis phase. For the approximately 90% of pediatric patients who present in the chronic phase of the disease, monotherapy with a TKI is the standard of care. The choice between the several generations of TKIs including, but not limited to, imatinib (first generation), dasatinib or nilotinib (second generation), ponatinib or bosutinib (third generation) to name just a few, is mainly stylistic or resource-dependent, as there is no clear winner from the few randomized studies in pediatrics. The goal with all treatment is to induce rapid molecular remission and prevent the development of mutations that cause resistance to TKIs. Studies have demonstrated that adult patients who achieve early and/or major molecular remissions can safely stop TKI therapy and maintain deep remissions. TKIs in children have been shown to affect growth among other side effects and, in pediatrics, there is great interest in safely discontinuing TKIs. Prospective studies testing this strategy in pediatrics are currently ongoing. In summary, TKIs have transformed CML, but the optimal TKI, duration, and the exact role of HSCT are still not defined in pediatrics.
Prognosis
There are several prognostic scoring schemas that accurately predict the outcome in adults in the context of a variety of therapies including TKIs. Prognostic include age, sex, spleen size, white count, basophil, eosinophil and blast count. However, none of these prognostic models have ever been prospectively tested in pediatric CML. In general, early cytogenetic and molecular responses are associated with favorable outcomes in both adult and pediatric studies.